HIV Prevention in a Time of COVID-19: A Report from the HIVR4P // Virtual Conference 2021

Fatima Laher, University of the Witwatersrand, Johannesburg, South Africa.
Simone I. Richardson, University of the Witwatersrand, Johannesburg, South Africa.
Philip Smith, The Desmond Tutu HIV Research Centre, Cape Town, South Africa.
Patrick S. Sullivan, Emory University, Atlanta, Georgia, USA.
Andrea G. Abrahams, University of Cape Town, Cape Town, South Africa.
Osaretin E. Asowata, Africa Health Research Institute, Durban, South Africa.
Patrick Bitangumutwenzi, Yowli Burundi, Bujumbura, Burundi.
Smritee Dabee, Seattle Children's Research Institute, Seattle, Washington, USA.
Annabell Dollah, Kenya medical Research Institute, Nairobi, Kenya.
Natalia Fernandez, IAVI Human Immunology Laboratory, London, United Kingdom.
Robert K. Langat, University of Nairobi, Nairobi, Kenya.
Devi Leena Bose, International AIDS Vaccine Initiative (IAVI), New Delhi, India.
Udom Likhitwonnawut, Vaccine Advocacy Resource Group, Bangkok, Thailand.
Ranajoy Mullick, International AIDS Vaccine Initiative (IAVI), New Delhi, India.
Rachel S. Resop, The George Washington University, Washington, District of Columbia, USA.
Jyoti Sutar, Indian Council of Medical Research (ICMR), Mumbai, India.
Ashaki Nzingha Thompson-Hall, SisterLove, Inc., Atlanta, United States.
Michael W. Traeger, Burnet Institute, Melbourne, Australia.
Marina Tuyishime, Duke University, Durham, North Carolina, USA.
Jacque Wambui, AFROCAB Treatment Access Partnerships, Nairobi, Kenya.
Linda-Gail Bekker, The Desmond Tutu HIV Research Centre, Cape Town, South Africa.
Pontiano Kaleebu, Uganda Virus Research Institute & MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
Sheena McCormack, MRC Clinical Trials Unit, London, United Kingdom.
David H. O'Connor, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Mitchell Warren, AVAC, New York, New York, USA.
Tamara Torri, International AIDS Society, Geneva, Switzerland.
Bargavi Thyagarajan, International AIDS Society, Geneva, Switzerland.

Document Type

Journal Article

Publication Date

5-1-2022

Journal

AIDS research and human retroviruses

Volume

38

Issue

5

DOI

10.1089/AID.2021.0138

Keywords

HIV; HIVR4P; PrEP; South Africa; TaSP; antiretrovirals; broadly neutralizing antibodies (bNAbs); clinical trials; microbicides; prevention; vaccine

Abstract

The HIV Research for Prevention (HIVR4P) conference catalyzes knowledge sharing on biomedical HIV prevention interventions such as HIV vaccines, antibody infusions, pre-exposure prophylaxis, and microbicides in totality-from the molecular details and delivery formulations to the behavioral, social, and structural underpinnings. HIVR4P // Virtual was held over the course of 2 weeks on January 27-28 and February 3-4, 2021 as the coronavirus disease 2019 (COVID-19) pandemic continued to inflict unprecedented harm globally. The HIVR4P community came together with 1,802 researchers, care providers, policymakers, implementers, and advocates from 92 countries whose expertise spanned the breadth of the HIV prevention pipeline from preclinical to implementation. The program included 113 oral and 266 poster presentations. This article presents a brief summary of the conference highlights. Complete abstracts, webcasts, and daily rapporteur summaries may be found on the conference website (https://www.hivr4p.org/).

Department

School of Medicine and Health Sciences Student Works

Link to Full Text

Share

COinS